IC7: a gp130 receptor ligand to treat type 2 diabetes

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/1042465

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Over the past decade work from our group has identified that a group of proteins, termed gp130 receptor cytokines, can lead to improvements in both causes and symptoms of type 2 diabetes in both animals and humans. Unfortunately, due to side effects, clinical trial using analogues of these proteins have failed. We believe we know why this is the case and we now have developed new, improved peptides that should overcome these side effects. We hope that we have created a novel drug that will help treat type 2 diabetes.

Funded Activity Details

Start Date: 01-01-2013

End Date: 01-01-2015

Funding Scheme: Project Grants

Funding Amount: $598,833.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Medical Physiology not elsewhere classified

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

hepatic steatosis | insulin resistance | metabolic disease | obesity | type 2 diabetes mellitus (non-insulin dependent diabetes mellitus)

Related Links